Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 2/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747303 | 0.97 | ALDH1A1 (0.40) | EGLN1ALDH1A1AKR1C1FASNPCSK9 | |
| SCHEMBL21747254 | 0.95 | ALDH1A1 (0.39) | EGLN1ALDH1A1AKR1C1FASNNPSR1 | |
| SCHEMBL21747227 | 0.93 | PCSK9 (0.35) | EGLN1ALDH1A1AKR1C1FASNPCSK9 | |
| SCHEMBL21747414 | 0.86 | EGLN1 (0.40) | EGLN1ALDH1A1NPSR1MEN1LMNA | |
| SCHEMBL21747351 | 0.85 | ERAP1 (0.36) | EGLN1ALDH1A1FABP4SMN1; SMN2KDM4E | |
| SCHEMBL21747407 | 0.85 | HSD11B1 (0.36) | EGLN1ALDH1A1FABP4KDM4E | |
| SCHEMBL21747422 | 0.85 | ALDH1A1 (0.36) | EGLN1ALDH1A1AKR1C1MEN1LMNA | |
| SCHEMBL21747367 | 0.84 | EGLN1 (0.37) | EGLN1ALDH1A1FASNFABP4KDM4E | |
| SCHEMBL21747387 | 0.84 | ERAP1 (0.38) | EGLN1ALDH1A1FABP4KDM4E | |
| SCHEMBL21747277 | 0.84 | HSD11B1 (0.38) | EGLN1FABP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| CN-108484598-B | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | EGLN1 4427/4885ALDH1A1 1770/4885AKR1C1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.